metformin
Commercial- Indications
- Diabetes
Company intelligence / Profile preview
Exemed Pharmaceuticals manufactures a broad range of small molecule APIs and finished dosage forms. The company has commercialized multiple products in regulated markets with USFDA/EU GMP-approved facilities. It also sponsors late-stage clinical trials in India for novel fixed-dose combinations such as dapagliflozin + eplerenone in chronic kidney disease patients. Financials indicate strong growth with revenue over $60 million USD in FY2023 and an expanding global footprint.
11 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Exemed Pharmaceuticals.